Does Aetna Cover Prolia? A Complete Coverage Guide

What Is Prolia and Why Does Coverage Complexity Exist?

Prolia is the brand name for denosumab, a RANK-ligand inhibitor that reduces osteoclast activity and slows bone resorption. The FDA approved denosumab 60 mg for postmenopausal osteoporosis in June 2010, and subsequent approvals followed for men with osteoporosis and for glucocorticoid-induced bone loss [1]. Because Prolia is a biologic administered by a clinician, it is usually processed under the medical benefit rather than the pharmacy benefit, which creates a layer of billing complexity not present with an oral pill.

Why the Medical Benefit Creates Extra Hurdles

Most oral osteoporosis drugs (alendronate, risedronate) are covered under the pharmacy benefit with a simple co-pay. Prolia's J-code (J0897) routes it through medical claims, which means different deductibles, different cost-sharing structures, and a separate prior authorization pathway. Patients and prescribers sometimes receive a pharmacy denial even when the drug is approvable under medical benefits. Calling Aetna with the specific J-code before the first administration avoids that confusion.

The Clinical Case for Prolia

The FREEDOM trial (N=7,868) showed that denosumab 60 mg every 6 months reduced new vertebral fractures by 68% over 36 months compared with placebo (relative risk 0.32, 95% CI 0.26 to 0.40, P<0.001) [2]. New hip fracture risk dropped by 40% in the same population [2]. These figures are part of what Aetna's clinical policy bulletin cites when defining who qualifies for coverage.

Aetna's Standard Coverage Criteria for Prolia

Aetna covers Prolia when a member meets a defined set of clinical criteria. The exact wording is in Aetna's Clinical Policy Bulletin (CPB) for denosumab, which is publicly posted and updated periodically. The core requirements across most commercial and Medicare Advantage plans share a common framework even if plan-level details differ.

Diagnosis Requirements

To qualify, a member typically needs one of the following:

• Postmenopausal osteoporosis confirmed by dual-energy X-ray absorptiometry (DXA) showing a T-score of <-2.5 at the lumbar spine or hip, OR a T-score between -1.0 and -2.5 with a documented fragility fracture.
• Male osteoporosis with a T-score of <-2.5, or high fracture risk as defined by FRAX (a 10-year probability of major osteoporotic fracture >20% or hip fracture >3%) [3].
• Glucocorticoid-induced osteoporosis in adults taking the equivalent of prednisone 7.5 mg/day or more for 6 months or longer.
• Bone loss associated with hormone ablation therapy in men with nonmetastatic prostate cancer or women with breast cancer (this indication uses the higher-dose formulation Xgeva, not the Prolia dose, so confirm the exact indication and dose before submission).

The American College of Rheumatology's 2022 guidelines for glucocorticoid-induced osteoporosis list denosumab as an option after or alongside bisphosphonates depending on fracture risk category [4].

Step Therapy: The Bisphosphonate-First Rule

Most Aetna plans require documented failure, intolerance, or contraindication to at least one oral bisphosphonate before approving Prolia. Alendronate 70 mg weekly and risedronate 35 mg weekly are the most common first-line agents referenced. "Failure" generally means either a new fragility fracture on therapy or continued bone loss (worsening T-score by >0.05 g/cm²) after at least 12 months of consistent use.

Exceptions to step therapy are typically granted when:

• The patient has esophageal disease (Barrett esophagus, active esophagitis) that makes oral bisphosphonates unsafe.
• Creatinine clearance is <35 mL/min (bisphosphonates are renally contraindicated at this threshold per FDA labeling) [5].
• The patient has a documented GI absorption disorder (celiac disease, post-bariatric anatomy) that prevents reliable oral drug uptake.

Prior Authorization Documentation Checklist

Prescribers submitting a PA for Prolia should gather:

1. DXA report with T-scores (within the past 24 months for most plans)
2. FRAX score printout if using high-fracture-risk as the qualifying criterion
3. 12-month prescription fill history for any prior bisphosphonate (or chart note documenting contraindication)
4. ICD-10 code (M81.0 for age-related osteoporosis in a postmenopausal woman is most common)
5. Prescriber's attestation of the injection site (office, infusion center, or home health)

How Much Does Prolia Cost With Aetna?

Even with approval, out-of-pocket costs vary significantly based on plan design.

Approved Claim Cost-Sharing

Under the medical benefit, Prolia is subject to the plan's deductible and coinsurance rather than a flat drug co-pay. A member on a plan with a $2,000 deductible who has not met it will pay the negotiated rate (often $900, $1,200 per injection) until the deductible clears. After that, a 20% coinsurance on a $1,000 negotiated rate means $200 per injection, or $400 per year.

Medicare Advantage members generally face Part B cost-sharing rules, which set coinsurance at 20% of the Medicare-approved amount after the Part B deductible ($240 in 2024) [6].

Manufacturer Savings Programs

Amgen's Prolia patient support program, Amgen SupportPlus, offers a co-pay card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per injection for eligible members. Medicare beneficiaries do not qualify for co-pay cards under federal anti-kickback rules, but low-income Medicare patients may qualify for Extra Help (Low Income Subsidy), which can reduce Part B coinsurance significantly [7].

The table below summarizes typical cost scenarios:

| Coverage Scenario | Estimated Per-Injection Cost | |---|---| | Commercial plan, deductible met, 20% coinsurance | $180, $240 | | Commercial plan, deductible not met | $900, $1,200 (negotiated rate) | | Medicare Advantage, 20% Part B coinsurance | $150, $200 after deductible | | No insurance, list price | ~$1,400 | | With Amgen co-pay card (commercial only) | $0, $25 |

What to Do If Aetna Denies Prolia

Denials fall into three main categories: administrative (missing documentation), step-therapy (bisphosphonate not tried), and medical necessity (criteria not met). Each has a different fix.

Administrative Denials

These are the most common and the easiest to resolve. A denial code of "missing clinical information" almost always means the PA submission lacked one of the documents listed above. The prescriber's office should call Aetna's provider line, confirm exactly what is missing, and resubmit. Most administrative denials are resolved within 5 to 10 business days on resubmission.

Step-Therapy Denials

If the denial states the patient has not tried a bisphosphonate, the prescriber must either document a contraindication or submit records showing prior bisphosphonate use. Under the 21st Century Cures Act, insurers including Aetna are required to grant a step-therapy exception when the required drug is contraindicated, has been ineffective, or when the time required to try it would cause irreversible harm [8]. A clinician attestation citing one of these grounds is usually sufficient for a first-level appeal.

Medical Necessity Denials

These require a formal peer-to-peer review. The treating physician calls Aetna's medical director line (usually within 72 hours of the denial notice) and presents the clinical rationale directly. Data from the FREEDOM trial [2] and the patient's specific T-score and fracture history are the most persuasive elements. If the peer-to-peer fails, a formal written appeal citing the National Osteoporosis Foundation's clinical guidelines (which support Prolia as appropriate when T-score is <-2.5 or when bisphosphonates are contraindicated) strengthens the case [3].

External Review

If all internal appeals fail, members have the right to an independent external review under the ACA. External review organizations are required to apply evidence-based medical standards rather than plan-specific criteria. Studies of external review outcomes across all drug classes show that patients win approximately 39 to 45% of externally reviewed cases [9].

Aetna Medicare Advantage vs. Commercial Plans: Key Differences

Aetna offers both commercial (employer-sponsored and individual marketplace) plans and Medicare Advantage plans. Coverage rules differ in important ways.

Commercial Plans

Commercial plan criteria follow Aetna's Clinical Policy Bulletin, which is updated approximately every 12 to 24 months. Step therapy is standard, but the exceptions are well-defined. Co-pay cards are available through Amgen.

Medicare Advantage Plans

Prolia under Medicare Advantage is billed as a Part B drug. Coverage criteria for Part B drugs must be at least as generous as original Medicare, but Medicare Advantage plans may add prior authorization requirements that original Medicare does not have. The Centers for Medicare and Medicaid Services (CMS) finalized rules in 2024 tightening MA plan authority to impose step therapy on Part B drugs, which may reduce the number of step-therapy denials for Prolia going forward [10].

Original Medicare (not Medicare Advantage) covers Prolia under Part B when it is administered in a physician's office or outpatient hospital setting, with no step-therapy requirement, though the treating provider must document medical necessity.

Switching From Prolia: A Coverage Caution

One clinical point that affects coverage decisions: stopping Prolia without transitioning to another antiresorptive agent carries significant fracture risk. The FREEDOM extension data showed that discontinuing denosumab led to rapid bone loss and a rebound increase in vertebral fracture risk within 12 months of the last injection [11]. The Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacotherapy explicitly states that "patients who discontinue denosumab should receive an antiresorptive agent to maintain bone density gains" [12].

This means that if a patient loses Aetna coverage mid-treatment (plan change, job loss, aging into Medicare), a bridge therapy plan must be in place. Most physicians transition patients to zoledronic acid 5 mg IV or oral alendronate for at least 12 months after the last Prolia injection.

How to Check Your Specific Aetna Plan's Prolia Coverage

Coverage confirmation requires three steps:

1. Call the member services number on the back of your Aetna ID card and ask specifically about CPT code 96372 (subcutaneous injection administration) and J-code J0897 (denosumab 60 mg). Ask whether prior authorization is required and what the PA criteria are.

2. Ask your prescriber's office to run a benefits verification through Aetna's provider portal before scheduling the injection. Benefit verifications typically return within 24 to 48 hours and confirm deductible status, coinsurance rate, and PA requirements.

3. Request a copy of the applicable Clinical Policy Bulletin (CPB number 0649 for denosumab as of the most recent public posting). Aetna's CPBs are publicly available at aetna.com under the "Clinical Policy Bulletins" section. Reviewing the exact criteria lets the prescriber tailor the PA submission.

Alternatives If Prolia Remains Uncovered

If Aetna ultimately does not cover Prolia for a specific patient, clinically validated alternatives exist.

Oral Bisphosphonates

Alendronate 70 mg weekly (generic available, often <$10/month with GoodRx) is the most cost-effective first-line option and is covered by virtually all Aetna plans at a Tier 1 or Tier 2 co-pay. The 2022 ACR guideline supports it as first-line for most patients with glucocorticoid-induced osteoporosis at moderate to high fracture risk [4].

Zoledronic Acid

Zoledronic acid 5 mg IV once yearly (generic available as of 2021) is also covered under Aetna's medical benefit and often has fewer step-therapy barriers than Prolia because it has a longer history and is available in generic form. The HORIZON Key Fracture Trial (N=7,765) showed zoledronic acid reduced vertebral fracture risk by 70% over 3 years [13].

Romosozumab

Romosozumab (Evenity, 210 mg SC monthly for 12 months) is a sclerostin inhibitor approved for postmenopausal women with severe osteoporosis. It carries an FDA black box warning for cardiovascular events and is generally reserved for patients at very high fracture risk [1]. Aetna covers it under criteria similar to Prolia, so a patient denied Prolia on step-therapy grounds will likely face the same hurdle with romosozumab.

Raloxifene

Raloxifene 60 mg daily is a selective estrogen receptor modulator covered at Tier 2 on most Aetna formularies. It reduces vertebral fracture risk but does not significantly reduce hip fracture risk, making it a limited substitute for patients whose primary concern is hip fracture [3].

Documentation Language That Strengthens a Prolia PA

Physicians who frame PA requests using the same language Aetna's policy uses get approved faster. Three phrases that align with Aetna's CPB criteria:

• "Patient has a DXA-confirmed T-score of [X] at the [femoral neck / lumbar spine], consistent with osteoporosis per WHO criteria."
• "Patient has documented intolerance to oral bisphosphonate therapy in the form of [GI adverse effects / esophageal stricture / CrCl <35 mL/min], rendering that class contraindicated."
• "Patient sustained a low-trauma fragility fracture of the [hip / vertebra / wrist] while adherent to oral bisphosphonate therapy for [X] months, meeting the definition of bisphosphonate failure."

The Endocrine Society's guideline notes that "for postmenopausal women with osteoporosis at high risk of fracture, particularly those with a prior vertebral fracture, denosumab is an effective treatment option" [12]. Quoting this directly in a peer-to-peer review adds guideline weight to the clinical argument.